|
US5948786A
(en)
|
1996-04-12 |
1999-09-07 |
Sumitomo Pharmaceuticals Company, Limited |
Piperidinylpyrimidine derivatives
|
|
AU3445100A
(en)
|
2000-03-24 |
2001-10-08 |
Pharmagene Lab Ltd |
Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists
|
|
HN2001000224A
(es)
|
2000-10-19 |
2002-06-13 |
Pfizer |
Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
|
|
GB0031295D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Naphthalene derivatives
|
|
GB0031302D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
GB0103269D0
(en)
|
2001-02-09 |
2001-03-28 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
CA2481532A1
(en)
|
2002-04-12 |
2003-10-23 |
Pfizer Inc. |
Imidazole compounds as anti-inflammatory and analgesic agents
|
|
CA2482382A1
(en)
|
2002-04-12 |
2003-10-23 |
Pfizer Inc. |
Pyrazole compounds as anti-inflammatory and analgesic agents
|
|
CA2485485A1
(en)
|
2002-05-23 |
2003-12-04 |
Theratechnologies Inc. |
Antagonistic peptides of prostaglandin e2 receptor subtype ep4
|
|
DK1603893T3
(da)
|
2003-01-29 |
2008-09-08 |
Asterand Uk Ltd |
EP4 -Receptorantagonister
|
|
WO2005019218A1
(ja)
|
2003-08-26 |
2005-03-03 |
Teijin Pharma Limited |
ピロロピリミジンチオン誘導体
|
|
RS20060143A
(sr)
|
2003-09-03 |
2008-06-05 |
Pfizer Inc., |
Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
|
|
EP1678147B1
(en)
|
2003-09-15 |
2012-08-08 |
Lead Discovery Center GmbH |
Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
|
|
GB0324269D0
(en)
|
2003-10-16 |
2003-11-19 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
EP1723132A1
(en)
|
2004-02-12 |
2006-11-22 |
Asterand Uk Limited |
Ep2 receptor agonists
|
|
CN1950334A
(zh)
|
2004-05-04 |
2007-04-18 |
辉瑞有限公司 |
邻位取代的芳基或杂芳基酰胺化合物
|
|
MXPA06011555A
(es)
|
2004-05-04 |
2006-12-15 |
Pfizer |
Compuestos de metil-aril o heteroaril-amida sustituida.
|
|
GT200500284A
(es)
*
|
2004-10-15 |
2006-03-27 |
Aventis Pharma Inc |
Pirimidinas como antagonistas del receptor de prostaglandina d2
|
|
US8013159B2
(en)
|
2005-05-19 |
2011-09-06 |
Merck Canada Inc. |
Quinoline derivatives as EP4 antagonists
|
|
WO2006128129A2
(en)
|
2005-05-26 |
2006-11-30 |
Synta Pharmaceuticals Corp. |
Method for treating cancer
|
|
AR060403A1
(es)
|
2006-04-12 |
2008-06-11 |
Sanofi Aventis |
Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
|
|
CA2648729A1
(en)
|
2006-04-24 |
2007-11-01 |
Merck Frosst Canada Ltd. |
Indole amide derivatives as ep4 receptor antagonists
|
|
US7705035B2
(en)
|
2006-06-12 |
2010-04-27 |
Merck Frosst Canada Ltd. |
Indoline amide derivatives as EP4 receptor ligands
|
|
US20080280891A1
(en)
|
2006-06-27 |
2008-11-13 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents and uses thereof
|
|
WO2008008059A1
(en)
|
2006-07-12 |
2008-01-17 |
Locus Pharmaceuticals, Inc. |
Anti-cancer agents ans uses thereof
|
|
EP2044056B1
(en)
*
|
2006-07-14 |
2012-08-22 |
Novartis AG |
Pyrimidine derivatives as alk-5 inhibitors
|
|
WO2008017164A1
(en)
|
2006-08-11 |
2008-02-14 |
Merck Frosst Canada Ltd. |
Thiophenecarboxamide derivatives as ep4 receptor ligands
|
|
WO2008039882A1
(en)
|
2006-09-30 |
2008-04-03 |
Sanofi-Aventis U.S. Llc |
A combination of niacin and a prostaglandin d2 receptor antagonist
|
|
ES2400293T3
(es)
|
2007-02-26 |
2013-04-08 |
Merck Canada Inc. |
Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4
|
|
EP2141147A1
(en)
|
2007-03-26 |
2010-01-06 |
Astellas Pharma Inc. |
Ornithine derivative
|
|
AU2008232265B2
(en)
|
2007-03-26 |
2013-02-28 |
Merck Canada Inc. |
Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
|
|
EP2014657A1
(de)
|
2007-06-21 |
2009-01-14 |
Bayer Schering Pharma Aktiengesellschaft |
Diaminopyrimidine als Modulatoren des EP2-Rezeptors
|
|
EP2460787A1
(en)
|
2007-07-03 |
2012-06-06 |
Astellas Pharma Inc. |
Amide compounds and their use as PGE2 antagonists.
|
|
WO2009047359A1
(en)
|
2007-10-12 |
2009-04-16 |
Ingenium Pharmaceuticals Gmbh |
Inhibitors of protein kinases
|
|
CA2714743C
(en)
|
2008-02-19 |
2017-01-17 |
Janssen Pharmaceutica N.V. |
Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
|
|
US8598355B2
(en)
|
2008-05-14 |
2013-12-03 |
Astellas Pharma Inc. |
Amide compound
|
|
US20130225528A1
(en)
|
2008-05-21 |
2013-08-29 |
Ariad Pharmaceuticals, Inc. |
Phosphorus Derivatives as Kinase Inhibitors
|
|
US8404736B2
(en)
|
2008-08-14 |
2013-03-26 |
Beta Pharma Canada Inc. |
Heterocyclic amide derivatives as EP4 receptor antagonists
|
|
GB2474813B
(en)
|
2008-09-19 |
2014-05-28 |
Biotechnology Res Corp Ltd |
Triterpenoid compounds and methods of use thereof
|
|
AU2009295308A1
(en)
|
2008-09-25 |
2010-04-01 |
Merck Canada Inc. |
Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists
|
|
US8906914B2
(en)
|
2009-08-18 |
2014-12-09 |
Janssen Pharmaceutica Nv |
Ethylene diamine modulators of fatty acid hydrolase
|
|
WO2011063181A1
(en)
|
2009-11-23 |
2011-05-26 |
Lexicon Pharmaceuticals, Inc. |
Methods and assays for the treatment of irritable bowel syndrome
|
|
BR112012029647A2
(pt)
|
2010-05-21 |
2016-08-02 |
Chemilia Ab |
novos derivados de pirimidinas
|
|
EP3061751A1
(en)
|
2010-09-21 |
2016-08-31 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition
|
|
JP5273689B2
(ja)
|
2010-09-29 |
2013-08-28 |
株式会社エヌビィー健康研究所 |
ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
|
|
CN103298787A
(zh)
|
2010-11-17 |
2013-09-11 |
诺瓦提斯公司 |
3-(氨基芳基)-吡啶化合物
|
|
WO2012066065A1
(en)
|
2010-11-17 |
2012-05-24 |
Novartis Ag |
Phenyl-heteroaryl amine compounds and their uses
|
|
WO2012076063A1
(en)
|
2010-12-10 |
2012-06-14 |
Rottapharm S.P.A. |
Pyridine amide derivatives as ep4 receptor antagonists
|
|
WO2012103071A2
(en)
|
2011-01-25 |
2012-08-02 |
Eisai R&D Management Co., Ltd. |
Compounds and compositions
|
|
JP5886411B2
(ja)
|
2011-03-24 |
2016-03-16 |
ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ |
新規のピリミジン誘導体
|
|
WO2012149528A1
(en)
|
2011-04-29 |
2012-11-01 |
Exelixis, Inc. |
Inhibitors of inducible form of 6-phosphofructose-2-kinase
|
|
WO2012177618A1
(en)
|
2011-06-20 |
2012-12-27 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
|
RU2565596C2
(ru)
|
2011-07-04 |
2015-10-20 |
Роттафарм Биотек С.Р.Л. |
Производные циклических аминов в качестве антагонистов рецептора ер4
|
|
EP2554662A1
(en)
|
2011-08-05 |
2013-02-06 |
M Maria Pia Cosma |
Methods of treatment of retinal degeneration diseases
|
|
US20150004175A1
(en)
|
2011-12-13 |
2015-01-01 |
Yale University |
Compositions and Methods for Reducing CTL Exhaustion
|
|
SI3459942T1
(sl)
|
2012-04-24 |
2021-05-31 |
Vertex Pharmaceuticals Incorporated |
Inhibitorji DNA-PK
|
|
TWI572597B
(zh)
|
2012-06-29 |
2017-03-01 |
美國禮來大藥廠 |
二甲基－苯甲酸化合物
|
|
AR091429A1
(es)
|
2012-06-29 |
2015-02-04 |
Lilly Co Eli |
Compuestos de fenoxietil piperidina
|
|
EP2711364A1
(en)
|
2012-09-21 |
2014-03-26 |
Chemilia AB |
4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
|
|
RU2672916C2
(ru)
|
2012-11-27 |
2018-11-21 |
Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг |
Производные пиримидин-2,4-диамина для лечения рака
|
|
UA115576C2
(uk)
|
2012-12-06 |
2017-11-27 |
Байєр Фарма Акцієнгезелльшафт |
Похідні бензимідазолу як антагоністи ер4
|
|
EP2765128A1
(en)
|
2013-02-07 |
2014-08-13 |
Almirall, S.A. |
Substituted benzamides with activity towards EP4 receptors
|
|
TW201443004A
(zh)
|
2013-02-15 |
2014-11-16 |
Lilly Co Eli |
苯氧基乙氧基化合物
|
|
TWI636046B
(zh)
|
2013-05-17 |
2018-09-21 |
美國禮來大藥廠 |
苯氧基乙基二氫－１ｈ－異喹啉化合物
|
|
BR112015030315B1
(pt)
|
2013-06-12 |
2022-10-04 |
Kaken Pharmaceutical Co., Ltd |
Derivado de 4-alquinilimidazol e produto farmacêutico que o compreende e antagonista de receptor de ep4
|
|
ES2642074T3
(es)
|
2013-09-04 |
2017-11-15 |
Bristol-Myers Squibb Company |
Compuestos útiles como inmunomoduladores
|
|
CN105814028B
(zh)
|
2013-09-06 |
2018-02-16 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的1，2，4‑*二唑衍生物
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
SI3057959T1
(en)
|
2013-10-17 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
DNA-PK INHIBITORS
|
|
PT3424920T
(pt)
|
2013-10-17 |
2020-07-07 |
Vertex Pharma |
Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk
|
|
CN105793242B
(zh)
|
2013-12-17 |
2018-02-16 |
伊莱利利公司 |
苯氧基乙基环状胺衍生物及其作为ep4受体调节剂的活性
|
|
EA028675B1
(ru)
|
2013-12-17 |
2017-12-29 |
Эли Лилли Энд Компани |
Соединения диметилбензойной кислоты
|
|
TW201607943A
(zh)
|
2013-12-19 |
2016-03-01 |
拜耳製藥公司 |
作為ｅｐ４配體之新穎苯并咪唑衍生物
|
|
TW201623277A
(zh)
|
2014-03-26 |
2016-07-01 |
安斯泰來製藥股份有限公司 |
醯胺化合物
|
|
WO2015167825A1
(en)
|
2014-04-29 |
2015-11-05 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
|
WO2015179615A1
(en)
|
2014-05-23 |
2015-11-26 |
Eisai R&D Management Co., Ltd |
Combination therapies for the treatment of cancer
|
|
CN106794181A
(zh)
|
2014-06-04 |
2017-05-31 |
托马斯·黑勒戴药物研究基金会 |
用于治疗炎性和自身免疫性病况的mth1抑制剂
|
|
WO2016021742A1
(en)
|
2014-08-07 |
2016-02-11 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds as ep4 receptor antagonists
|
|
MX389142B
(es)
|
2015-01-09 |
2025-03-04 |
Ono Pharmaceutical Co |
Compuestos espiro triciclicos.
|
|
WO2017014323A1
(en)
|
2015-07-23 |
2017-01-26 |
Takeda Pharmaceutical Company Limited |
1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
|
|
CA3002144C
(en)
|
2015-10-16 |
2024-01-23 |
Eisai R&D Management Co., Ltd. |
Ep4 antagonists
|
|
CR20180323A
(es)
|
2015-11-20 |
2018-08-06 |
Idorsia Pharmaceuticals Ltd |
Derivados de indol n-sustituídos como moduladores de los receptores de pge2
|
|
EP3484870B1
(en)
|
2016-07-13 |
2022-11-16 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
CN110612296A
(zh)
|
2017-05-18 |
2019-12-24 |
爱杜西亚药品有限公司 |
作为pge2受体调节剂的苯基衍生物
|
|
JP7093791B2
(ja)
|
2017-05-18 |
2022-06-30 |
イドーシア ファーマシューティカルズ リミテッド |
Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
|
|
MX394108B
(es)
|
2017-05-18 |
2025-03-21 |
Idorsia Pharmaceuticals Ltd |
Derivados de indol n-sustituidos.
|
|
TW201900180A
(zh)
|
2017-05-18 |
2019-01-01 |
瑞士商愛杜西亞製藥有限公司 |
嘧啶衍生物
|
|
AU2018268311B2
(en)
|
2017-05-18 |
2022-02-10 |
Idorsia Pharmaceuticals Ltd |
Pyrimidine derivatives as PGE2 receptor modulators
|